Search the Newsreel

Neuronetics outlines 2026 revenue of $160M-$164M while shifting NeuroStar to broader ownership models

Earnings Call Insights: Neuronetics (STIM) Q2 2026 MANAGEMENT VIEW * "I'm pleased to report the second quarter began to reflect our steady execution against the goals I cited last quarter. Total revenue was $41.6 million, up approximately 9% versus the second quarter of last …

Neuronetics Q2 Earnings Call Highlights

Key Points Interested in Neuronetics, Inc.? Here are five stocks we like better. Q2 results improved significantly: Revenue rose 9.1% year over year to $41.6 million, while the net loss narrowed to $3.4 million and adjusted EBITDA turned positive at $0.3 million. Greenbrook was …

LVMH: Share transactions disclosure

LVMH Paris, August 11th, 2026 The disclosure of share transactions carried out from August 3rd to August 7th, 2026, was sent to the AMF on August 11th 2026. As required by current law, this document is publically available and can be consulted on the …

If You Invested $1,000 in WaveDancer, Inc. (WAVD)

This article analyzes the historical performance of a $1,000 investment in WaveDancer, Inc. (WAVD) over different periods, providing details on its annual returns and cumulative growth. It also explains WaveDancer's significant transformation from an IT services company to a medical technology and AI company …

Neurogene Q2 Results: EPS widens to $(1.53), misses estimates

Neurogene (NASDAQ:NGNE) Stock Price Down 7.8% on Disappointing Earnings

Neurogene (NASDAQ:NGNE) Posts Earnings Results, Misses Expectations By $0.11 EPS

Neuronetics (NASDAQ:STIM) Announces Earnings Results

Earnings call transcript: Neuronetics tops Q2 2026 forecasts as stock jumps 23%

Neuronetics publishes investor presentation on NeuroStar TMS, Greenbrook clinic network strategy

Neuronetics has released an investor presentation detailing its NeuroStar TMS and Greenbrook clinic network strategy. The company provided FY 2026 revenue guidance of $160 million to $164 million, projecting 7% to 10% year-on-year growth, alongside a gross margin outlook of 48% to 50%. It …

Neuronetics STIM Draws Buy Rating As Vertical Psychiatry Platform Scales Up

Neuronetics (STIM) has received a "Buy" rating and a $5 target price from BTIG, signaling bullish sentiment due to its expanding depression-treatment technology adoption and vertically integrated psychiatry platform. The company's acquisition of 93 Greenbrook-operated treatment centers and the establishment of a National Center …

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification

NeuroOne Medical Technologies Corporation has announced it received ISO 13485-2016 certification, an international standard for Quality Management Systems in the Medical Device Industry. This certification allows NeuroOne to pursue international marketing opportunities for its Evo® Cortical and Evo® sEEG Electrodes, and the OneRF® Brain …

Euronet to offer credit issuing platform in Peru

Euronet has partnered with Unibanca, a Peruvian payment services company, to provide its CoreCard credit issuing platform as a software-as-a-service (SaaS) solution in Peru. This collaboration aims to enhance Unibanca's service offerings, enabling them to provide advanced credit solutions like Buy Now Pay Later …

Firefly Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Why Euro Sun Mining Inc stock surged yesterday

Neuronetics stock soars 15% on second quarter earnings beat

Neuronetics (NASDAQ:STIM) reported strong second-quarter results, surpassing analyst expectations with an adjusted loss per share of -$0.05 and revenue of $41.6 million. The company's stock surged over 15% in pre-market trading, driven by a 9.1% year-over-year revenue increase, primarily from its Greenbrook clinic segment. …

Neuronetics Reports Second Quarter 2026 Results, Highlights Revenue Growth and Improved Adjusted EBITDA

Neuronetics, Inc. reported a 9.1% increase in total revenue to $41.6 million for Q2 2026, driven by a 16.8% rise in Greenbrook healthcare clinic revenue. The company also significantly improved its adjusted EBITDA to $0.3 million and reduced its net loss to $3.4 million. …

What is Noble Financial's Estimate for EuroDry Q3 Earnings?

Euroseas Ltd. Sets Date for the Release of Second Quarter 2026 Results, Conference Call and Webcast

Euroseas Ltd. has announced that it will release its financial results for the second quarter ended June 30, 2026, on Monday, August 25, 2026. The company will also host a conference call and webcast on the same day to discuss the results. This event …

Neurogene: Q2 Earnings Snapshot

Euronet Worldwide (NASDAQ:EEFT): A Decent Value Stock Worth Researching

B&M European Value Retail (LON:BME) Stock Crosses Above 50-Day Moving Average - Here's What Happened

Neuronetics (STIM) Earnings Date and Reports 2026 $STIM

Neurogene (NGNE) Earnings Date and Reports 2026

Transactions in Own Shares

Coca-Cola Europacific Partners PLC has confirmed the repurchase of a total of 294,868 ordinary shares between August 3 and August 7, 2026, as part of its ongoing share buyback program announced on February 17, 2026. These repurchases occurred on both US and London trading …

Euroholdings Ltd (EHLD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Coca-Cola Europacific Partners (CCEP) Stock Forecasts

Morningstar published an analyst report on Coca-Cola Europacific Partners (CCEP), highlighting that product innovation and World Cup activations are driving demand. CCEP is identified as the second-largest bottler in the Coca-Cola system, primarily operating in Europe, Australasia, and Southeast Asia. The report notes CCEP …

Euro Pratik Sales Q1FY27 net profit rises 116% to ₹200.5 crore

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

Coca-Cola Europacific Partners buys back 294,868 shares By Investing.com

Coca-Cola Europacific Partners plc repurchased 294,868 ordinary shares between August 3 and August 7 as part of its share buyback program. The company acquired shares on both US and London trading venues through Goldman Sachs & Co. LLC and Goldman Sachs International, with prices …

Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing?

Neurocrine Biosciences (NBIX) has commenced a Phase 1 study for its obesity treatment candidate, NBIP 1968, following positive Q2 and H1 2026 financial results. Despite recent stock momentum and a current share price of $163.41, Simply Wall St's analysis suggests the company might be …

Earnings Estimates Rising for EuroDry (EDRY): Will It Gain?

Coca-Cola Europacific Partners koopt 294.868 eigen aandelen terug

Euro Pratik Sales Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Eurofins Scientific SE: Weekly Report on Share Repurchases from 03rd August to 07th August 2026

LUXEMBOURG, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC …